MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

A

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

18.04 -0.82

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.93

Max

18.09

Galvenie mērījumi

By Trading Economics

Ienākumi

67M

-681K

Pārdošana

-2.9M

17M

P/E

Sektora vidējais

48.528

88.032

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+13.2% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 8. janv.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

24M

368M

Iepriekšējā atvēršanas cena

18.86

Iepriekšējā slēgšanas cena

18.04

Ziņu noskaņojums

By Acuity

40%

60%

114 / 374 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. janv. 22:45 UTC

Galvenie tirgus virzītāji

GH Research Shares Up, Plans to Provide Update on New Drug Application

2026. g. 2. janv. 22:13 UTC

Tirgus saruna
Peļņas

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 2. janv. 21:07 UTC

Peļņas

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2026. g. 2. janv. 20:09 UTC

Tirgus saruna

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2026. g. 2. janv. 19:48 UTC

Tirgus saruna

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2026. g. 2. janv. 18:53 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. janv. 18:53 UTC

Tirgus saruna

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2026. g. 2. janv. 17:56 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2026. g. 2. janv. 17:50 UTC

Tirgus saruna

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2026. g. 2. janv. 17:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 2. janv. 16:33 UTC

Tirgus saruna

Remittances to Mexico Fell 5.7% in November -- Market Talk

2026. g. 2. janv. 16:18 UTC

Tirgus saruna

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2026. g. 2. janv. 15:48 UTC

Peļņas

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2026. g. 2. janv. 15:17 UTC

Tirgus saruna

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2026. g. 2. janv. 15:01 UTC

Tirgus saruna

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2026. g. 2. janv. 15:00 UTC

Peļņas

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2026. g. 2. janv. 14:56 UTC

Tirgus saruna

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2026. g. 2. janv. 14:20 UTC

Tirgus saruna

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2026. g. 2. janv. 14:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. janv. 14:13 UTC

Tirgus saruna

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2026. g. 2. janv. 13:39 UTC

Tirgus saruna

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2026. g. 2. janv. 13:01 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2026. g. 2. janv. 12:45 UTC

Tirgus saruna

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2026. g. 2. janv. 11:48 UTC

Tirgus saruna

European Gas Climbs as Cold Weather Bites -- Market Talk

2026. g. 2. janv. 11:36 UTC

Tirgus saruna

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2026. g. 2. janv. 11:30 UTC

Tirgus saruna

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2026. g. 2. janv. 11:29 UTC

Tirgus saruna

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2026. g. 2. janv. 11:15 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

13.2% augšup

Prognoze 12 mēnešiem

Vidējais 20.5 USD  13.2%

Augstākais 25 USD

Zemākais 16 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

114 / 374 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat